Nonsuppressed Glucagon After Glucose Challenge as a Potential Predictor for Glucose Tolerance
- PMID: 27986831
- DOI: 10.2337/db16-0354
Nonsuppressed Glucagon After Glucose Challenge as a Potential Predictor for Glucose Tolerance
Abstract
Glucagon levels are classically suppressed after glucose challenge. It is still not clear as to whether a lack of suppression contributes to hyperglycemia and thus to the development of diabetes. We investigated the association of postchallenge change in glucagon during oral glucose tolerance tests (OGTTs), hypothesizing that higher postchallenge glucagon levels are observed in subjects with impaired glucose tolerance (IGT). Glucagon levels were measured during OGTT in a total of 4,194 individuals without diabetes in three large European cohorts. Longitudinal changes in glucagon suppression were investigated in 50 participants undergoing a lifestyle intervention. Only 66-79% of participants showed suppression of glucagon at 120 min (fold change glucagon120/0 <1) during OGTT, whereas 21-34% presented with increasing glucagon levels (fold change glucagon120/0 ≥1). Participants with nonsuppressed glucagon120 had a lower risk of IGT in all cohorts (odds ratio 0.44-0.53, P < 0.01). They were also leaner and more insulin sensitive and had lower liver fat contents. In the longitudinal study, an increase of fold change glucagon120/0 was associated with an improvement in insulin sensitivity (P = 0.003). We characterize nonsuppressed glucagon120 during the OGTT. Lower glucagon suppression after oral glucose administration is associated with a metabolically healthier phenotype, suggesting that it is not an adverse phenomenon.
© 2017 by the American Diabetes Association.
Comment in
-
Postprandial Suppression of Glucagon Secretion: A Puzzlement.Diabetes. 2017 May;66(5):1123-1125. doi: 10.2337/dbi16-0075. Diabetes. 2017. PMID: 28507213 No abstract available.
Similar articles
-
Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus.Metabolism. 2005 Sep;54(9):1168-73. doi: 10.1016/j.metabol.2005.03.024. Metabolism. 2005. PMID: 16125528
-
Lifestyle intervention in individuals with normal versus impaired glucose tolerance.Eur J Clin Invest. 2007 Jul;37(7):535-43. doi: 10.1111/j.1365-2362.2007.01820.x. Eur J Clin Invest. 2007. PMID: 17576204
-
Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance.Diabetes Res Clin Pract. 2006 May;72(2):117-27. doi: 10.1016/j.diabres.2005.09.018. Epub 2005 Nov 16. Diabetes Res Clin Pract. 2006. PMID: 16297488 Clinical Trial.
-
The potential for lifestyle change to influence the progression of impaired glucose tolerance to non-insulin-dependent diabetes mellitus.Diabet Med. 1996 Nov;13(11):938-45. doi: 10.1002/(SICI)1096-9136(199611)13:11<938::AID-DIA274>3.0.CO;2-P. Diabet Med. 1996. PMID: 8946151 Review.
-
Impaired glucose tolerance and impaired fasting glucose--a review of diagnosis, clinical implications and management.Diab Vasc Dis Res. 2005 Feb;2(1):9-15. doi: 10.3132/dvdr.2005.007. Diab Vasc Dis Res. 2005. PMID: 16305067 Review.
Cited by
-
Genetic and clinical characterization of familial renal glucosuria.Clin Kidney J. 2023 Oct 17;17(2):sfad265. doi: 10.1093/ckj/sfad265. eCollection 2024 Feb. Clin Kidney J. 2023. PMID: 38344682 Free PMC article.
-
The relationship between glucose and the liver-alpha cell axis - A systematic review.Front Endocrinol (Lausanne). 2023 Jan 5;13:1061682. doi: 10.3389/fendo.2022.1061682. eCollection 2022. Front Endocrinol (Lausanne). 2023. PMID: 36686477 Free PMC article.
-
Postprandial Dynamics of Proglucagon Cleavage Products and Their Relation to Metabolic Health.Front Endocrinol (Lausanne). 2022 Jun 29;13:892677. doi: 10.3389/fendo.2022.892677. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35872982 Free PMC article. Clinical Trial.
-
Mathematical Model of Glucagon Kinetics for the Assessment of Insulin-Mediated Glucagon Inhibition During an Oral Glucose Tolerance Test.Front Endocrinol (Lausanne). 2021 Mar 22;12:611147. doi: 10.3389/fendo.2021.611147. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33828527 Free PMC article.
-
Low-Density Lipoprotein Cholesterol Is Associated With Insulin Secretion.J Clin Endocrinol Metab. 2021 May 13;106(6):1576-1584. doi: 10.1210/clinem/dgab147. J Clin Endocrinol Metab. 2021. PMID: 33693827 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
